Hologic (FRA:HO1) Other Stockholders Equity: €0 Mil (As of Dec. 2025)


FRA:HO1 Hologic Inc FRA:HO1
57 GF Score
Price €65.00
GF Value €70.17
! 5 Warning Signs
View Full Analysis

What is Hologic Other Stockholders Equity?

Hologic FRA:HO1 57 Other Stockholders Equity is €0 Mil as of Dec. 2025. GuruFocus rates FRA:HO1 with a GF Score™ of 57/100 and a GF Value™ of €70.17. The stock has 5 warning signs investors should review.

Hologic's Other Stockholders Equity for the quarter that ended in Dec. 2025 was €0 Mil.

Hologic's quarterly Other Stockholders Equity declined from Jun. 2025 (€0 Mil) to Sep. 2025 (€0 Mil) but then stayed the same from Sep. 2025 (€0 Mil) to Dec. 2025 (€0 Mil).

Hologic's annual Other Stockholders Equity increased from Sep. 2023 (€0 Mil) to Sep. 2024 (€0 Mil) but then declined from Sep. 2024 (€0 Mil) to Sep. 2025 (€0 Mil).

Hologic Other Stockholders Equity Historical Data

* Premium members only.

The historical data trend for Hologic's Other Stockholders Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Hologic Other Stockholders Equity Chart

Hologic Annual Data
Trend Sep16 Sep17 Sep18 Sep19 Sep20 Sep21 Sep22 Sep23 Sep24 Sep25
Other Stockholders Equity
Get a 7-Day Free Trial Premium Member Only Premium Member Only -0.00 0.00 0.00 0.00 0.00

Hologic Quarterly Data
Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25
Other Stockholders Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 -0.00 0.00 0.00 0.00
FRA:HO1
57GF Score
Hologic Inc FRA:HO1
Other Stockholders Equity is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Hologic Other Stockholders Equity Calculation

Other Stockholders Equity is instruments issued by the company that cannot be identified by other specific items in the Equity section. GuruFocus lists following items in "Total Stockholders Equity" section:
Common Stock
Preferred Stock
Retained Earnings
Accumulated other comprehensive income (loss)
Additional Paid-In Capital
Treasury Stock
Other Stockholders Equity

What does a Other Stockholders Equity of €0 Mil mean?
Hologic (FRA:HO1) has a Other Stockholders Equity of €0 Mil as of Dec. 2025. Other Equity is instruments issued by the company that cannot be identified by other specific items in the Equity section. View historical data on Hologic and its competitors.
Is Hologic's Other Stockholders Equity too high?
Hologic's current Other Stockholders Equity is €0 Mil. Overall, Hologic has a GF Score™ of 57/100, reflecting its overall financial health beyond just this single metric.
How does Hologic's Other Stockholders Equity compare to WST and COO?
Hologic's Other Stockholders Equity of €0 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Stockholders Equity for a Medical Devices & Instruments company?
A good Other Stockholders Equity depends on the Medical Devices & Instruments industry context. However, Other Stockholders Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Stockholders Equity mean?
A high Other Stockholders Equity can signal that a stock is expensive relative to its fundamentals. Other Equity is instruments issued by the company that cannot be identified by other specific items in the Equity section. View historical data on Hologic and its competitors. Hologic's current Other Stockholders Equity is €0 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Hologic stock overvalued right now?
Hologic (FRA:HO1) has a current Other Stockholders Equity of €0 Mil. The stock's GF Value™ is €70.17, compared to a current price of €65.00 — trading 7.4% below its estimated fair value. The current Other Stockholders Equity is €0 Mil. Hologic's overall GF Score™ is 57/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Stockholders Equity calculated?
Other Stockholders Equity is calculated from a company's financial statements. For Hologic (FRA:HO1), the current Other Stockholders Equity is €0 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Hologic (FRA:HO1) Overvalued in 2026?

Based on GuruFocus' analysis, Hologic stock appears to be undervalued. The current stock price of €65.00 is trading 7.4% below its estimated GF Value™ of €70.17.

Key valuation signals for FRA:HO1:

  • Other Stockholders Equity: €0 Mil
  • GF Value™: €70.17 vs. price of €65.00 (7.4% below fair value)
  • GF Score™: 57/100 with 5 warning signs

No single metric tells the full story. See the FRA:HO1 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Hologic Business Description

Address 250 Campus Drive, Marlborough, MA, USA, 01752
Hologic manufactures proprietary products for the healthcare needs of women. The company operates in four segments: diagnostics (44% of total sales), breast health (38%), surgical (16%), and skeletal health (2%). While the company traditionally focused on breast health, the acquisition of Gen-Probe put greater emphasis on commercial diagnostics. The United States accounts for the largest portion of the firm's revenue (69%), followed by Europe (20%), Asia (8%), and other international markets (3%). Hologic is headquartered in Bedford, Massachusetts.
57GF Score

Get the complete analysis for FRA:HO1

Other Stockholders Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€65.00
Price
€70.17
GF Value